The results support previous findings of Gaich et al., who utilized the FGF-21 analogue LY2405319 in a randomized, placebo-controlled double-blind proof-of-concept trial in patients with obesity and T2D and supplied the first proof-of-concept example for the biological potential of FGF-21 in humans [34]. The gene discussed is FGF21; the disease is Obesity.